Revenio Group Oyj - Company Announcement

Revenio Group Corporation: Revenio's Icare launches new product generation

Revenio Group Corporation, Stock Exchange Release, December 22, 2015 at 9.00

REVENIO'S ICARE LAUNCHES NEW PRODUCT GENERATION

Icare Finland Oy, a subsidiary of Revenio Group, will launch a new ic100
tonometer on the European markets in January, to replace the TA01i tonometer
introduced to the markets in 2003. The company expects the new device gradually
to replace the TA01i in the markets. Around 50,000 Icare tonometers have been
sold since 2003.

The Icare ic100 tonometer has already been awarded a CE mark for the European
markets, gaining relevant sales permit for all EU countries. The company has
reinforced its sales and marketing organization in preparation for sales of the
new product generation. A sales license application is estimated to be submitted
to the FDA in the US during Q1/2016.

In developing of the ic100 Icare tonometer, the focus has been in improving
ergonomics, measurement of intraocular pressure and modern design. Icare® AMS, a
familiar feature of the Icare HOME tonometer, allows a series of six
measurements at a single touch of a button. Based on a green and red light,
Icare® EasyPos guides the tonometer into the correct position, while the Icare®
EasyNav interface and a large color screen make the device easy to use.

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The
Revenio Group comprises the business operations of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, which specializes in osteoporosis screening
and monitoring. In addition, Revenio has identified new growth opportunities
relating to health tech in which common denominators are screening, follow-up
and the global need to make cost savings in health care via preventive measures.
Revenio seeks vigorous growth in health technology, both organically and through
acquisitions and mergers.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
margin for continuing operations standing at 27.5%. Revenio Group Corporation
has been listed in Nasdaq Helsinki.

[HUG#1975270]